Systemic buffers inhibit carcinogenesis in TRAMP mice.
OBJECTIVE
Hypoxia and acidosis develop in in situ tumors as cellular expansion increases the diffusion distance of substrates and metabolites from blood vessels deep to the basement membrane. Prior studies of breast and cervical cancer revealed that cellular adaptation to microenvironmental hypoxia and acidosis is associated with the transition from in situ to invasive cancer. We hypothesized that decreased acidosis in intraductal tumors would alter environmental selection pressures for acid adapted phenotypes and delay or prevent evolution to invasive cancer.


METHODS
A total of 37 C57BL/6 TRAMP mice were randomized to a control group or to 1 of 4 treatment groups. In the latter groups 200 mM sodium bicarbonate were added to drinking water starting between ages 4 and 10 weeks.


RESULTS
In all 18 controls prostate cancer developed that was visible on 3-dimensional ultrasound at a mean age of 13 weeks. They died within 52 weeks (median 37). When sodium bicarbonate therapy commenced before age 6 weeks in 10 mice, all reached senescence (age 76 weeks) without radiographic evidence of prostate cancer. Histological sections of the prostates in this cohort showed hyperplasia but no cancer in 70% of mice and minimal well differentiated cancer in the remainder. When therapy commenced after age 6 weeks in 9 mice, prostate cancer development was no different from that in controls.


CONCLUSIONS
Immunohistochemical staining for carbonic anhydrase 9 in regions of ductal hyperplasia showed increased expression in controls vs the early treatment group. Regional pH perturbation in in situ tumors may be a simple, inexpensive and effective cancer prevention strategy.
Department of Radiology, H. Lee Moffitt Cancer Center, Tampa, Florida 33612, USA.
Arig
A
Ibrahim-Hashim
Heather H
HH
Cornnell
Dominique
D
Abrahams
Mark
M
Lloyd
Marilyn
M
Bui
Robert J
RJ
Gillies
Robert A
RA
Gatenby
D000136:Acid-Base Equilibrium / Q000187:drug effects / Q000502:physiology*; D000222:Adaptation, Physiological / Q000502:physiology; D000818:Animals; D002021:Buffers; D015687:Cell Hypoxia / Q000187:drug effects / Q000502:physiology*; D002471:Cell Transformation, Neoplastic / Q000473:pathology*; D004195:Disease Models, Animal; D006801:Humans; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D009361:Neoplasm Invasiveness / Q000473:pathology; D009368:Neoplasm Transplantation; D010641:Phenotype; D011467:Prostate / Q000473:pathology; D011470:Prostatic Hyperplasia / Q000473:pathology; D011471:Prostatic Neoplasms / Q000473:pathology*; D017693:Sodium Bicarbonate / Q000494:pharmacology*; D014183:Transplantation, Heterologous
D002021:Buffers; D017693:Sodium Bicarbonate